THE SECOND ANNUAL PHARMACEUTICAL INDUSTRY REGULATORY & COMPLIANCE SUMMIT
June 10-12, 2001
Health Care Compliance Association
In Association with:
Food and Drug Law Institute (FDLI)
Anthony O. Boswell, Esq.
Corporate Compliance Officer and Corporate Counsel, Laidlaw, Inc.
Charles M. Brock, Esq.
Chief Ethics and Compliance Officer, Abbott Laboratories
Oliver M. Johnson, II, Esq.
Officer, Merck & Co., Inc
Paul E. Kalb, MD, JD
Partner, Sidley & Austin
Richard J. Kenny, Jr., Esq.
Assistant General Counsel, AstraZeneca Pharmaceuticals, LP
Michael K. Loucks, Esq.
Health Care Fraud Chief, United States Attorney's Office, District of Massachusetts
Douglas M. Lankler, Esq.
Corporate Counsel, Compliance, Pfizer Inc.
Roger W. Louis, Esq.
Chief Compliance Officer, Genzyme Corporation
John Markus, Esq.
Senior Vice President, Fresenius Medical Care North America
Vickie McCormick, Esq.
Integrity Officer, UnitedHealth Group
Joseph W. Metro, Esq.
Partner, Reed Smith, LLP
Lewis Morris, Esq.
Assistant Inspector General for Legal Affairs, Office of the Inspector General, US Department of Health and Human
Arjun Rajaratnam, Esq.
Compliance Officer, Global Pharmaceuticals, GlaxoSmithKline
Mary E. Riordan, Esq.
Senior Counsel, Office of Counsel to the Inspector General, HHS-OIG
Brent Saunders, JD, MBA
Director, PricewaterhouseCoopers and Founder, Privacy
James Sheehan, Esq.
Assistant United States Attorney, United States Attorney's Office, Eastern District of Pennsylvania
Professor Malcolm K. Sparrow, Ph.D.
Lecturer in Public Policy, John F. Kennedy School of
Government, Harvard University
Robert L. Steinmeier
Corporate 21 CFR Part II Program Director, Abbott Laboratories
David Waterbury, Esq.
Senior Counsel, Washington State Attorney General's Office, Medicaid Fraud Control Unit